Three of the four products including Trastuzumab, Bevacizumab, Rituximab belong to the oncology segment, while Etanercept is used to treat auto-immune disease.
As per the terms of the agreement, Natco will manufacture drug products, undertake local clinical trials, file registration of dossiers, to apply for market authorizations and commercialize the product in India and other Asian countries.
Natco expects to complete the mAb initiative in a period of 24 to 36 months.